Valuation
- Market cap
- —
- Revenue TTM
- $6,990,000
- Net income TTM
- $-45,220,000
- P/E (trailing)
- —
- P/E (forward)
- —
- Profit margin
- -646.44%
- Debt to equity
- 0.40
Trading
- Volume
- 200
- Avg volume
- 12,204
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 7%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- $5.00
Company profile
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, a...
Show more
Scorpius Holdings, Inc., through its subsidiary Scorpius BioManufacturing, operates as an integrated contract development and manufacturing organization. The company engages in clinical and commercial drug substance manufacturing; and release and stability testing activities. It is also involved in the provision of various process development services, including upstream and downstream development and optimization, and analytical method development solutions, as well as cell line development, testing, and characterization services. The company serves the biotechnology and biopharmaceutical industries. The company was formerly known as NightHawk Biosciences, Inc. and changed its name to Scorpius Holdings, Inc. in February 2024. Scorpius Holdings, Inc. was incorporated in 2008 and is based in San Antonio, Texas.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 919 240 7133
- Website
- https://www.scorpiusbiologics.com
- Address
- 1305 East Houston Street, San Antonio, United States
Latest news
No headlines yet.
